GLP-1 Receptor Agonists: A New Frontier in Neurodegenerative Disease Research?

A recent review published in the Journal of Clinical Investigation examined the biological mechanisms, translational evidence, and clinical potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as disease-modifying therapies for neurodegenerative diseases (NDDs).

Background on Neurodegenerative Diseases

By 2040, neurodegenerative diseases are projected to become the second leading cause of death globally. The rates of conditions such as Alzheimer’s and Parkinson’s disease have increased within the aging population, yet few pharmacological treatments can alter their disease course.

Diabetes mellitus is associated with an increased risk of developing these disorders, highlighting a crucial connection between metabolism and neurodegeneration. Drugs originally designed for diabetes target several of these shared pathways. Rigorous, biomarker-driven research is required to determine if these drugs can protect the brain.

Brain Insulin Resistance: A Central Link

NDDs like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis share overlapping biological characteristics to varying degrees. Key molecular processes linking these conditions include brain insulin resistance, mitochondrial dysfunction, inflammation, and toxic protein accumulation.

Brain insulin resistance is a central mechanism connecting these processes.

In a healthy brain, insulin regulates synaptic plasticity, mitochondrial function, and neuronal survival. When insulin signaling is disrupted, neurons lose the ability to efficiently use glucose. This contributes to tau hyperphosphorylation, amyloid-beta accumulation, alpha-synuclein aggregation, and microglial activation. Clinically, these processes are associated with progressive cognitive and motor decline.

GLP-1RAs, commonly used for type 2 diabetes mellitus and obesity, activate pathways that overlap with insulin signaling. By potentially restoring metabolic balance, they may interrupt the cycle linking insulin resistance and neurodegeneration.

Potential Mechanisms of GLP-1RAs

Restoring Mitochondrial Function and Cellular Energy

Mitochondrial dysfunction occurs early in many NDDs. Impaired mitochondria produce less adenosine triphosphate and excessive reactive oxygen species, contributing to neuronal injury. GLP-1RAs may help maintain cerebral glucose metabolism, but consistent cognitive benefits have not been established.

Reducing Protein Aggregation and Enhancing Autophagy

Many NDDs are characterized by improperly folded proteins, such as amyloid-beta and tau in Alzheimer’s disease, and alpha-synuclein in Parkinson’s disease. Activation of the glucagon-like peptide-1 receptor stimulates pathways that enhance autophagy and proteostasis. Preclinical studies have shown reduced toxic protein burden and preserved neuronal integrity, though definitive disease-modifying effects in humans remain unproven.

Controlling Neuroinflammation

Chronic neuroinflammation accelerates neurodegeneration. GLP-1RAs inhibit inflammasome activity and suppress nuclear factor kappa B signaling. They promote anti-inflammatory immune phenotypes and reduce oxidative stress. Benefits have been observed in experimental models of multiple sclerosis, but consistent clinical translation has not yet been demonstrated.

Protecting Synapses and Neural Networks

Synaptic dysfunction often precedes neuronal death. GLP-1RAs increase brain-derived neurotrophic factor, stabilize dendritic spines, and enhance synaptic resilience, primarily in preclinical models. Preserving synaptic integrity may help maintain daily functioning for longer periods.

The Gut-Immune-Brain Axis

Dysbiosis of gut microbiota has been associated with neurodegeneration. GLP-1RA treatment has been linked to improved epithelial barrier function, reduced lipopolysaccharide-driven inflammation, and increased beneficial microbial taxa, largely in experimental or associative studies. GLP-1RAs may also help stabilize the blood-brain barrier.

Clinical Evidence Across Disorders

For Alzheimer’s disease, small trials suggest preserved cerebral glucose metabolism and slower cortical atrophy, though cognitive outcomes remain mixed. Large phase III trials of semaglutide are currently ongoing.

In Parkinson’s disease, early studies of exenatide suggested motor benefit, but a recent phase III trial reported negative clinical findings. A phase II trial of lixisenatide suggested modest slowing of motor progression.

Observational studies report a lower incidence of dementia and Parkinson’s disease among long-term GLP-1RA users, although causality is not established. Evidence for multiple system atrophy, amyotrophic lateral sclerosis, Huntington’s disease, and multiple sclerosis remains limited and inconsistent.

Conclusion

GLP-1RAs demonstrate broad neuroprotective potential across mechanistic, preclinical, and early clinical domains. They target biological drivers shared among NDDs, including insulin resistance, mitochondrial dysfunction, inflammation, and protein aggregation. While mechanistic and early clinical evidence is strongest for Alzheimer’s disease and Parkinson’s disease, findings remain inconclusive.

Interpretation is complicated by variability in central nervous system penetration, patient selection, outcome measures, tolerability, adherence, and potential effects on body weight and frailty in older adults.

Carefully designed, biomarker-guided trials in earlier disease stages are required to determine if these therapies meaningfully alter long-term neuropathology and functional outcomes.